Article Text
Correspondence
Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al
Statistics from Altmetric.com
I read with interest the recent case–control study by Potere et al, which describes the potential efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia and hyperinflammation.1 Since publication of this analysis, new information on anti-inflammatory therapies in COVID-19 has become available. The RECOVERY trial randomised 2104 patients with COVID-19 to receive dexamethasone 6 mg daily or usual care for up to 10 …